Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Meilian Zhang
Wenhuo Xie
Jianbin Li
Jiaping Zheng
Yu Zhou
机构：
[1] Fujian Medical University,Department of Ultrasound, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics
[2] Fujian Medical University,Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy
[3] School of Health,Department of Rehabilitation Medicine
[4] Fujian Medical University,undefined
来源：
Archives of Women's Mental Health | 2024年 / 27卷
关键词：
Postpartum depression; Brexanolone; Pharmacovigilance; Antidepressants;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：35 / 44
页数：9
相关论文
共 50 条
  • [21] A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS)
    Zhao, Jie
    Wang, Mei
    Yu, Qing
    Yang, Yi
    Zhang, Bin
    Zhan, Sanhua
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (07) : 937 - 948
  • [22] Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
    Teng, Chengwen
    Frei, Christopher R.
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) : 23 - 29
  • [23] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [24] A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)
    Shi, X.
    Cheng, Q.
    Zhao, Y. -z.
    Zou, S. -p.
    Sun, M. -h.
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (12) : 2047 - 2058
  • [25] A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)
    X. Shi
    Q. Cheng
    Y.-Z. Zhao
    S.-P. Zou
    M.-H. Sun
    Osteoporosis International, 2023, 34 : 2047 - 2058
  • [26] Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
    Hui Gao
    Xiaohan Zhai
    Yan Hu
    Hang Wu
    Scientific Reports, 15 (1)
  • [27] The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Huiping Hu
    Maochang Liu
    Zhiwen Fu
    Shijun Li
    Kaiping Wang
    Zi Huang
    BMC Pharmacology and Toxicology, 26 (1)
  • [28] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] A Real-World Safety Analysis of Upadacitinib Based on FDA Adverse Event Reporting System (FAERS)
    Zhao, Yazheng
    Cheng, Qian
    Zou, Shupeng
    Shi, Xuan
    Ouyang, Mengling
    Sun, Minghui
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023, 2023
  • [30] Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Kvist, Annika Vestergaard
    Faruque, Junaid
    Vallejo-Yague, Enriqueta
    Weiler, Stefan
    Winter, Elizabeth M.
    Burden, Andrea M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
12345